What Pro-Tel (Pyrantel) Treats: Main Uses and Benefits

Pro-Tel (Pyrantel) is commonly used when short-term symptomatic assistance is needed for specific intestinal worm infections. It is applied across domains where additional symptomatic support is needed, helping patients cope more steadily with difficult episodes.

The therapeutic domains include symptomatic management for pinworm (Enterobiasis), roundworm (Ascariasis), and hookworm.

---

Targeted Relief for Pinworm Infection Symptoms

This medication is commonly used to help with the groups of symptoms associated with pinworm. It assists with maintaining functional stability by easing the overall burden of symptoms that may appear suddenly or intensify over time, particularly the distressing symptoms related to physical discomfort, such as anal itching, which may create noticeable functional strain. Pro-Tel provides supportive relief that is relevant for managing symptoms that interfere with daily comfort. This approach is relevant for easing symptoms that interfere with daily comfort and may help patients cope more steadily with symptom fluctuations.

---

Supportive Management in Other Intestinal Worm Cases

Pro-Tel is also applicable in conditions characterized by symptomatic presentations of roundworm and hookworm infections. It is used in clinical settings marked by increased discomfort or tension, helping to address symptom clusters that may become intense or disruptive, such as gastrointestinal discomfort. The medication is relevant in contexts involving heightened systemic burden during acute episodes.

---

Quick Fact: Supports functional stability during episodes involving Symptoms that Interfere with Daily Functioning

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Restriction Profile

The official regulatory documentation for Pro-Tel (Pyrantel) establishes a clear eligibility profile for its over-the-counter use, primarily based on age, weight, and existing health conditions.

Populations Permitted for Unsupervised Use:

• Age and Weight: Adults, children 12 years of age and over, and children 2 years to under 12 years of age weighing at least 25 pounds are the only populations permitted to use the product without a doctor’s guidance.

Populations with Restricted or Prohibited Use:

Specific populations must not take this medicine unless expressly directed by a doctor (physician), as stated in the product warnings:

• Pediatric Exclusion: Children under 2 years old or those weighing less than 25 pounds must not use this product unless directed by a doctor, as safety and efficacy have not been established for this group for non-prescription use.
• Condition Restriction: Individuals who have liver disease must not use the product unless directed by a doctor.
• Physiological State: Women who are pregnant must not take this product unless directed by a doctor. Caution is also advised if breastfeeding.

Furthermore, use is generally contraindicated in any individual with a known hypersensitivity or allergy to Pyrantel Pamoate or any other ingredient in the formulation. Treatment is limited to a single dose; repeated use requires medical direction.

Interactions with other medicines and products

The interaction profile of Pyrantel Pamoate is defined by specific restrictions and official warnings concerning co-administration with other substances and the consideration of pre-existing health conditions, as documented in regulatory prescribing information.

---

Documented Pharmacodynamic Interactions

Co-administration with Piperazine compounds is restricted due to a documented pharmacodynamic antagonism. This means the medicines have opposing actions on the parasite, potentially reducing the therapeutic activity of both agents and therefore must not be administered simultaneously.

Drug Exposure Modification

Pyrantel Pamoate may increase the systemic exposure of certain co-administered drugs. Specifically, concurrent use with Theophylline has been documented to potentially increase the plasma concentration of Theophylline. Additionally, interactions have been noted with Sodium Iodide I-123 and I-131.

Interaction-Related Restrictions and Cautions

Category	Interacting Substance / Condition	Official Restriction or Outcome
Anthelmintics	Piperazine Compounds	Explicitly restricted; antagonistic effect.
Xanthine Derivatives	Theophylline	Risk of increased plasma concentration.
Population Caution	Pre-existing Hepatic Dysfunction	Use with specific caution as noted in regulatory warnings.

---

The regulatory structure emphasizes one absolute restriction concerning other anthelmintics (Piperazine) and advises caution for the potential to alter the exposure of co-administered Theophylline. This profile is further defined by a population-specific warning related to pre-existing liver disease.

Pyrantel Pamoate's mechanism of action is focused entirely on the susceptible parasitic organisms within the intestinal lumen. The molecule acts as a selective agonist at the nicotinic acetylcholine receptors ( nAChRs) found in the parasite's somatic muscle cells. This interaction causes sustained activation of the receptors, which functionally overstimulates the worm's neuromuscular system.

This sustained nAChR activation initiates a cascade: an abnormal influx of positive ions leads to sustained depolarization of the muscle cell membrane. This electrical state forces the parasite's musculature into a rigid, locked contraction known as tetanic (spastic) paralysis. This paralysis functionally removes the worm's ability to generate movement or maintain its position against the intestinal wall. The immobilized organisms are then passively cleared via the host's normal bowel movements. This effect is luminal-restricted and does not exert its paralyzing mechanism on parasites that have migrated beyond the gastrointestinal tract.

How Pro-Tel (Pyrantel) is Used

Pro-Tel, containing Pyrantel Pamoate, is administered strictly through the oral route. Its usage pattern is defined by a precise, weight-based calculation and a short duration, as outlined in prescribing information.

---

Official Administration Guidelines

Instruction	Detail
Route of administration	Oral administration only.
Dosing schedule	Calculated as 11 mg of Pyrantel Base per kilogram (kg) of body weight in a single dose. The maximum total dose administered must not exceed 1 gram (1000 mg) of Pyrantel Base.
Timing in relation to meals	May be taken at any time of day, with or without meals.
Preparation requirements	Oral suspension must be shaken well before use. It may be taken alone or mixed with milk or fruit juice.
Age-group rules	Not for use in children under 2 years of age or those weighing less than 25 pounds (11 kg) unless directed by a physician.

---

Procedural Context and Frequency

The standard regimen for Pyrantel is a single-dose treatment. For pinworm infection, this dose is often followed by a potential second dose 14 days later to address the parasite's life cycle, a temporal pattern noted in clinical overviews. The dose is required to be measured accurately using a special device, not a household spoon, to ensure the weight-based calculation is delivered correctly. The drug's label also specifies that a laxative is not necessary before, during, or after administration, simplifying the overall protocol for use.

These instructions define a standardized protocol where accurate dose calculation and adherence to the required single-dose and two-week repeat cycle establish the framework for the medication's use as determined by official bodies.

Research Evidence / Overview of Studies for Pyrantel (Pro-Tel)

---

Evidence for Use in Pinworm Infection (Enterobius vermicularis)

Research examining Pyrantel's use in pinworm infection includes short-term Randomized Controlled Trials (RCTs) and various comparative studies. The key outcomes measured were related to parasitological clearance rates, specifically tracking the absence of pinworm eggs or adult worms in samples taken shortly after administration. Findings reported in these studies highlight changes measured during the study period, often describing a pattern of change in infection status. Research highlights changes measured during the study period, which were often followed by the recurrence of infection. What remains uncertain is the long-term follow-up. Studies observing responses over defined time intervals are often limited in duration, meaning long-term effects are not fully established regarding sustained change in infection status.

Evidence for Use in Roundworm Infection (Ascaris lumbricoides)

Pyrantel was studied for roundworm infection in several RCTs and field studies. These studies monitored parasitological cure rates and the Egg Reduction Rate (ERR). Findings describe patterns observed in the studies that were often comparable to other standard treatments in terms of initial parasite clearance. However, the protocols for treatment used in the research were heterogeneous across studies, leading to variability in the specific reported outcomes. Data for certain groups remain insufficient, especially regarding patients with a very heavy burden of roundworm infection. The follow-up durations were limited in many studies, providing less insight into effects beyond the immediate post-treatment period.

---

Evidence in Special Populations and Uncertainties

Specific research on Pyrantel in special populations is limited. Data for certain groups remain insufficient, particularly for children under two years of age. Studies have examined Pyrantel in populations that include pregnant individuals, though limited information from controlled studies is available for this group. Comparative evidence is lacking from placebo-controlled trials for ethical reasons in current research. Research also describes some regional patterns where changes in infection status were less pronounced, indicating that findings were mixed and may be tied to geographical factors. Long-term effects are not fully established, which remains a universal limitation across all indications.

Key Studies & References

1. Pyrantel Pamoate - DailyMed (FDA Label Information for Human OTC Drug)

Common questions about Pro-Tel (Pyrantel) (FAQ)

---

Q: What are the main things Pro-Tel (Pyrantel) is approved to treat?

A: Official regulatory labeling confirms that Pro-Tel (Pyrantel) is approved for the treatment of infections caused by certain intestinal parasites. Specifically, the drug is indicated for pinworm (Enterobius vermicularis) and roundworm (Ascaris lumbricoides).

---

Q: How long does the effect of Pro-Tel (Pyrantel) last in the body?

A: Pyrantel Pamoate is characterized by poor absorption within the body, meaning most of the active ingredient remains in the gastrointestinal tract, where its primary action occurs. The small portion that is absorbed into the bloodstream is processed quickly. Official pharmacokinetic data indicates the drug has an elimination half-life of approximately 3 hours.

---

Q: What is the difference between Pyrantel Pamoate and Pyrantel?

A: Pyrantel Pamoate is the chemical salt form of the active drug, Pyrantel. The drug's strength and required administration are based on the amount of Pyrantel base that the Pamoate salt delivers. This distinction is used to define the standard calculation for administration.

---

Q: What common side effects are usually associated with Pro-Tel (Pyrantel)?

A: Regulatory documents list known adverse events, such as nausea, vomiting, diarrhea, abdominal cramps, headache, and dizziness. However, official sources often do not categorize these effects with terms like 'common' or 'rare' by providing numerical frequencies.

---

Q: Are there foods I should avoid while using Pro-Tel (Pyrantel)?

A: Official administration instructions indicate that Pro-Tel (Pyrantel) may be taken with or without food. The oral suspension form may also be mixed with milk or fruit juice. The official documents do not impose specific dietary restrictions for use.

---

Q: Does Pro-Tel (Pyrantel) have any known long-term effects?

A: Research overviews in regulatory documents note that studies examining the effects of Pyrantel Pamoate are often limited in duration. Consequently, the profile of effects that might occur or persist over a long period after treatment is not fully established.

---

Q: What happens if I miss a dose of Pro-Tel (Pyrantel)?

A: Official information describes the standard treatment as a single-dose regimen. Because the drug is typically administered as a single, one-time treatment, regulatory guidance does not include specific instructions for managing a missed dose.

---

Q: Is Pro-Tel (Pyrantel) effective against all types of worm infections?

A: Official product labeling specifies the intestinal parasites that Pro-Tel (Pyrantel) is indicated to treat, primarily pinworm and roundworm. The drug is generally not indicated or effective for other types of intestinal worm infections, such as whipworm or tapeworm.

---

Q: Are there any specific lifestyle changes recommended while taking Pro-Tel (Pyrantel)?

A: Official regulatory overviews emphasize that accompanying hygienic measures are considered an important factor in achieving successful outcomes, particularly for pinworm infection. Hygienic measures are noted to be important factors in the overall management of the condition.

---

Q: Is there a generic version of Pro-Tel (Pyrantel)?

A: Yes, the active ingredient in Pro-Tel, which is Pyrantel Pamoate, is available in generic, non-branded versions. These are manufactured and distributed by various companies under the name Pyrantel Pamoate.

---

Q: What color is the medicine Pro-Tel (Pyrantel)?

A: The official product description of the Pyrantel Pamoate oral suspension describes the liquid as being light tan or pale yellow in color.

---

Q: What are the ingredients in Pro-Tel (Pyrantel) besides the active drug?

A: Regulatory labeling lists the active drug, Pyrantel Pamoate, and also includes several inactive ingredients (excipients) in the formulation. These typically include substances like sorbitol, glycerin, and various flavoring or stabilizing agents.

---

Q: Can I crush or chew the Pro-Tel (Pyrantel) tablet?

A: Pro-Tel (Pyrantel) is available in forms intended for ease of use, such as an oral suspension and chewable tablets, which are designed to be chewed. For standard, non-chewable tablets, regulatory product information does not generally advise crushing the tablet.

---

Q: Is it important to treat the whole family with Pro-Tel (Pyrantel)?

A: For pinworm infection, official overviews frequently describe a protocol where all members of the household receive treatment. This approach is described because pinworm is easily spread within a home environment, and treating the household is considered a measure to address potential re-infection.

---

Q: Does Pro-Tel (Pyrantel) have any effects on blood tests?

A: Official documentation mentions that use of Pyrantel Pamoate has resulted in minor, transient increases in liver enzymes, such as AST and ALT. These changes are typically detected during blood tests.

---

Q: Does Pro-Tel (Pyrantel) work differently in children than in adults?

A: Clinical pharmacology data indicates that the drug's mechanism of action is the same in both adults and children. Differences in administration are only related to the weight-based dosing, as required by official administration protocols.

---

Q: Are there specific warnings about Pro-Tel (Pyrantel) for older adults?

A: Specific warnings tailored to the geriatric population (older adults) are not commonly highlighted in regulatory documentation. Regulatory information does not define a separate warning profile for this population.

---

Q: Why is Pyrantel Pamoate sometimes combined with other drugs?

A: While the Pro-Tel product is a single-ingredient formulation, the active component, Pyrantel Pamoate, is sometimes formulated in combination with other drugs, such as oxantel, in products used in other regulatory regions. This is typically done to treat mixed or multiple types of parasitic infections simultaneously.

---

Q: Is Pro-Tel (Pyrantel) used outside of the US?

A: Yes, Pyrantel Pamoate is widely used internationally and is included on the World Health Organization’s (WHO) List of Essential Medicines. It is authorized for use and available in many international regulatory jurisdictions, including those covered by the European Medicines Agency (EMA).

How to Store and Dispose of Pro-Tel (Pyrantel)?

The storage of Pro-Tel (Pyrantel Pamoate) must strictly follow the conditions specified in the official labeling to maintain product stability and safety. The medicine must be stored at a controlled room temperature, typically ranging from 15 C to 30 C (59 F to 86 F), and must not be frozen.

• Protection Requirements: The product must be protected from light, moisture, and excess heat. The container should be kept tightly closed and stored in its original packaging.
• Child Safety: All formulations must be kept strictly out of the sight and reach of children and stored in a childproof container.
• Disposal: Unused or expired Pyrantel Pamoate must be disposed of in accordance with local authority requirements. The medicine should not be discharged into drains or the environment.